po updat reflect anoth win keytruda
morn announc posit interim result studi
keytruda chemo first-lin non-smal cell lung cancer nsclc see
note confirm discuss fda convert exist
acceler approv full approv think could happen rel swiftli
although data-depend also note full result could present
april american associ cancer research meet base posit
updat made follow chang model result new po vs
probabl success peak market share keytruda chemo increas
vs vs respect result addit
revenu updat price-to-earnings vs reflect higher ep
growth rate recent market move continu valu base
blend dcf price-to-earnings multipl reiter buy rate given
favor mix attract valuat sustain return cash sharehold
diversifi revenu base substanti pipelin option driven keytruda
remind studi
recal confirmatori studi virtual ident trial
support fda acceler approv remain question address full
data present includ subgroup analysi determin benefit seen across
express driven subgroup patient data suggest
variabl group although patient number small conclus
 degre patient cross subsequ therapi determin data suggest
keytruda chemo given up-front superior chemo follow keytruda upon
progress patient chemo receiv therapi
landscap rapidli chang multipl readout
expect multipl competitor data readout nsclc near term includ
final os data roch tecentriq avastin chemo
tecentriq alimta abraxan azn mystic os data
 mrk keytruda express bmi
data
net dbt
increas reiter buy
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
rate buy offer attract valuat
good track record return cash
sharehold diversifi revenu base
substanti pipelin potenti keytruda
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object po base blend averag risk-adjust
discount cash flow dcf target price-to-earnings multipl appli ep
dcf assum wacc termin growth rate believ dcf
assumpt reason given minim contribut new keytruda
indic yet valid late-stag clinic studi erod
revenu base januvia/janumet zepati neg termin growth
target price-to-earnings multipl base regress analysi histor us major
pharma forward price-to-earnings multipl three-year forward compound-annual-growth-rate
risk competitor report result look substanti better
shown keytruda chemotherapi higher-than-anticip
price pressur diabet franchis neg result late-stag
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
